journal article·2019-12-04Open access

MiR-34b regulates cervical cancer cell proliferation and apoptosis

Zhen Cao, Gong Zhang, Conghua Xie, Yunfeng Zhou

Abstract

Objectives MiR-34b is a tumour suppressor in different kinds of carcinomas. This study investigated the role of miR-34b in proliferation and apoptosis of cervical cancer.Materials and methods The expression of miR-34b in 60 cervical cancer patients were quantified by RT-PCR and correlated with their clinicopathological parameters. Besides, there is a significant reverse relationship between miR-43b and TGF-β1 expression in tumour tissues. Cell proliferation and apoptosis was detected by CCK-8 assays and flow cytometry in cell lines transfected with miR-34b mimics. Western blotting, quantitative reverse transcription-PCR (RT-PCR) and luciferase assays were conducted to analyze the regulation of TGF-β1 by miR-34b in cell lines.Results Here, we found expression of miR-34b to be downregulated in cervical cancer in comparison with the adjacent normal tissues. Expression levels of miR-34b were associated with enhanced malignant potential, such as tumour stage and stromal invasion. The overexpression of miR-34b potently suppressed cell proliferation and induced the apoptosis of cell lines.Conclusions MiR-34b and TGF-β1 contribute to cervical cancer cell proliferation and apoptosis and are potential targets for cervical cancer therapeutics.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: MicroRNA in disease regulation · Cancer-related molecular mechanisms research · Circular RNAs in diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital, Wuhan University

References (25)

Show source-provided references
1. 10.6061/clinics/2018/e548s10.6061/clinics/2018/e548s ↗
2. 10.1080/13557858.2018.147166910.1080/13557858.2018.1471669 ↗
3. 10.1097/LGT.000000000000040010.1097/LGT.0000000000000400 ↗
4. 10.1002/cncr.3058810.1002/cncr.30588 ↗
5. 10.1155/2018/482654710.1155/2018/4826547 ↗
6. 10.1055/s-0034-139734410.1055/s-0034-1397344 ↗
7. 10.1016/j.ymeth.2018.09.01110.1016/j.ymeth.2018.09.011 ↗
8. 10.1002/jcb.2757510.1002/jcb.27575 ↗
9. 10.1159/00046794110.1159/000467941 ↗
10. 10.1155/2018/194286710.1155/2018/1942867 ↗
11. 10.3390/cancers1012049310.3390/cancers10120493 ↗
12. 10.1111/cpr.1252710.1111/cpr.12527 ↗
13. 10.1016/j.bbrc.2018.01.02310.1016/j.bbrc.2018.01.023 ↗
14. 10.18632/oncotarget.207310.18632/oncotarget.2073 ↗
15. 10.1002/jcb.2759810.1002/jcb.27598 ↗
16. 10.7555/JBR.31.2017004410.7555/JBR.31.20170044 ↗
17. 10.1007/s13277-016-5064-410.1007/s13277-016-5064-4 ↗
18. 10.4161/cc.2127810.4161/cc.21278 ↗
19. 10.12659/MSM.91158510.12659/MSM.911585 ↗
20. Dong J, Wang M, Ni D, et al. MicroRNA-217 functions as a tumour suppressor in cervical cancer cells through targeting Rho-associated protein kinase 1. Oncol Lett. 2018;16:5535–5542.
21. 10.18632/oncotarget.1076110.18632/oncotarget.10761 ↗
22. Dong F, Lou D. MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets. Mol Vis. 2012;18:537–546.
23. 10.3892/or.2012.206910.3892/or.2012.2069 ↗
24. 10.1186/s12935-018-0680-210.1186/s12935-018-0680-2 ↗
25. 10.1016/j.bbrc.2018.11.01710.1016/j.bbrc.2018.11.017 ↗